

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.*



**ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED**

**阿里健康信息技术有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 00241)**

**NOTICE OF ANNUAL GENERAL MEETING**

**NOTICE IS HEREBY GIVEN THAT** the annual general meeting of Alibaba Health Information Technology Limited (the “**Company**”) will be held at Plum-Seeking Grove Conference Room, VIP Meeting Room 802, Visitor Center, Area C, Alibaba Xixi Campus, No. 960-1, West Wen Yi Road, Yu Hang District, Hangzhou, China on August 30, 2024 at 10:30 a.m. (the “**Annual General Meeting**”) to transact the following businesses:

**As ordinary business**

1. To receive, consider and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and auditor for the year ended March 31, 2024.
2. To re-elect the following retiring directors of the Company (the “**Directors**”):
  - (a) Mr. Xu Haipeng as a non-executive Director;
  - (b) Ms. Huang Yi Fei (Vanessa) as an independent non-executive Director;
  - (c) Dr. Shao Rong as an independent non-executive Director; and
  - (d) Ms. Wu May Yihong as an independent non-executive Director.
3. To authorize the board (the “**Board**”) of Directors to fix the Directors’ remuneration.
4. To re-appoint Ernst & Young as the auditor of the Company and to authorize the Board to fix its remuneration.

### As special business

To consider and, if thought fit, pass each of the following resolutions, with or without amendments, as an ordinary resolution:

5. “**THAT:**

- (a) subject to paragraph (c) below and pursuant to the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange** ”), the exercise by the Directors during the Relevant Period (as hereinafter defined) of all powers of the Company to allot, issue and deal with additional shares of HK\$0.01 each (the “**Shares**”) in the share capital of the Company and to make or grant offers, agreements and options (including bonds, warrants and debentures convertible into Shares) which would or might require the exercise of such powers, subject to and in accordance with all applicable laws, be and is hereby generally and unconditionally approved;
- (b) the approval in paragraph (a) above shall authorize the Directors during the Relevant Period (as hereinafter defined) to make or grant offers, agreements and options (including bonds, warrants and debentures convertible into Shares) which would or might require the exercise of such powers after the end of the Relevant Period;
- (c) the aggregate number of additional Shares allotted or agreed conditionally or unconditionally to be allotted (whether pursuant to an option or otherwise) and issued by the Directors (including any treasury Shares sold and/or transferred or agreed conditionally or unconditionally to be sold and/or transferred) pursuant to the approval in paragraph (a) above, otherwise than pursuant to:
  - (i) a Rights Issue (as hereinafter defined); or
  - (ii) an issue of Shares upon the exercise of rights of subscription or conversion attaching to any warrants or convertible bonds issued by the Company or any securities which are convertible into Shares the issue of which warrants and other securities has previously been approved by the shareholders of the Company (the “**Shareholders**”); or
  - (iii) an issue of Shares upon the exercise of any options granted under any share option scheme or similar arrangement for the time being adopted for the grant or issue to eligible persons of Shares or rights to acquire Shares; or
  - (iv) an issue of Share as scrip dividends or similar arrangements providing for the allotment of Shares in lieu of the whole or part of a dividend on Shares in accordance with the bye-laws of the Company,

shall not in aggregate exceed 20% of the number of issued Shares of the Company as at the date of passing this resolution (excluding any treasury Shares), and the said approval shall be limited accordingly; and

(d) for the purpose of this resolution,

“Relevant Period” means the period from the passing of this resolution until:

- (i) the conclusion of the first annual general meeting of the Company following the passing of the resolution at which time it shall lapse unless, by ordinary resolution passed at that meeting, the authority is renewed, either unconditionally or subject to conditions;
- (ii) revoked or varied by ordinary resolution of the Shareholders in general meeting; or
- (iii) the expiration of the period within which the next annual general meeting of the Company is required to be held by the bye-laws of the Company, the Companies Act 1981 of Bermuda or any applicable laws of Bermuda;

whichever occurs first.

“Rights Issue” means an offer of Shares or warrants, options or other securities giving rights to subscribe for Shares, open for a period fixed by the Directors to the Shareholders or any class thereof on the register on a fixed record date in proportion to their then holdings of such Shares or any class thereof (subject to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements or having regard to any restrictions or obligations under the laws of, or the requirements of any recognized regulatory body or any stock exchange in any territory applicable to the Company).”

6. **“THAT:**

- (a) subject to paragraph (b) below, the exercise by the Directors during the Relevant Period (as defined in ordinary resolution no. 5 set out in the notice convening this meeting) of all the powers of the Company to purchase Shares (as defined in ordinary resolution no. 5 set out in the notice convening this meeting) on the Stock Exchange or on any other stock exchange on which the Shares may be listed and recognized by the Securities and Futures Commission of Hong Kong and the Stock Exchange for this purpose and, subject to and in accordance with the applicable laws and the requirements of the Listing Rules or of any other stock exchange as amended from time to time be and is hereby generally and unconditionally approved; and

- (b) the aggregate number of Shares to be purchased pursuant to the approval in paragraph (a) above shall not in aggregate exceed 10% of the number of issued Shares of the Company as at the date of passing this resolution (excluding any treasury Shares), and the said approval shall be limited accordingly.”
7. “**THAT** conditional upon the passing of the ordinary resolutions nos. 5 and 6 as set out in the notice convening this meeting, the general mandate granted to the Directors under ordinary resolution no. 5 as set out in the notice convening this meeting be and is hereby extended by the addition of an amount representing the number of issued Shares (as defined in ordinary resolution no. 5 set out in the notice convening this meeting) repurchased by the Company pursuant to the general mandate approved in ordinary resolution no. 6 as set out in the notice convening this meeting, provided that such amount of Shares so repurchased shall not in aggregate exceed 10% of the number of issued Shares of the Company as at the date of passing of the said resolution (excluding any treasury Shares).”
8. “**THAT**:
- (a) the proposed adoption (the “**Proposed Adoption**”) of a share award scheme of the Company (the “**2024 Share Award Scheme**”), details of which are set out in the section headed “Letter from the Board — Proposed Adoption of the 2024 Share Award Scheme and Termination of the 2014 Share Award Scheme” in the circular of the Company dated July 30, 2024 (the “**Circular**”), be and are hereby approved and confirmed, and any Director or company secretary of the Company be and is hereby authorised to execute all such documents and do all such other acts and things as he or she may, in his or her absolute discretion, consider necessary, desirable or expedient to effect the Proposed Adoption and any of the following matters;
- (b) the Scheme Mandate Limit (as defined in the 2024 Share Award Scheme) on the total number of shares that may be issued (and, together with treasury Shares which may be transferred, as applicable) in respect of all options and awards to be granted to the eligible participants under the 2024 Share Award Scheme and all the share schemes of the Company, being ten (10)% of the total number of Shares in issue (excluding treasury Shares) as at the date of the Annual General Meeting, be and is hereby approved and adopted; and
- (c) the Service Provider Sublimit (as defined in the 2024 Share Award Scheme) on the total number of shares that may be issued (and, together with treasury Shares which may be transferred, as applicable) in respect of all options and awards to be granted to eligible participants who are service providers under the 2024 Share Award Scheme and all the share schemes of the Company, being one (1)% of the total number of Shares in issue (excluding treasury Shares) as at the date of the Annual General Meeting, be and is hereby approved and adopted.”

9. “**THAT** subject to and conditional upon the passing of the ordinary resolution no. 8 as set out in the notice convening this meeting, the share award scheme adopted by the Company at the special general meeting held on November 24, 2014 and amended by the Company at the annual general meeting held on August 11, 2023 be and is hereby terminated upon the 2024 Share Award Scheme becoming adopted (after the fulfilment of all the conditions as set out in the 2024 Share Award Scheme).”

**As special business**

To consider and, if thought fit, pass with or without amendments, the following resolution as a special resolution:

10. “**THAT** the proposed amendments to the bye-laws of the Company (the “**Proposed Amendments**”), details of which are set out in the section headed “APPENDIX III — PROPOSED AMENDMENTS TO THE BYE-LAWS” in the Circular, be and are hereby approved and confirmed, and any Director or company secretary of the Company be and is hereby authorised to execute all such documents and do all such other acts and things as he or she may, in his or her absolute discretion, consider necessary, desirable or expedient to effect the Proposed Amendments and any of the foregoing.”

By Order of the Board  
**ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED**  
**ZHU Shunyan**  
*Chairman*

Hong Kong, July 30, 2024

*Registered Office:*

Victoria Place  
5th Floor  
31 Victoria Street  
Hamilton, HM 10  
Bermuda

*Head office and principal place of business in Hong Kong:*

26/F Tower One  
Times Square  
1 Matheson Street  
Causeway Bay  
Hong Kong

*Notes:*

1. All resolutions at the Annual General Meeting will be taken by poll pursuant to the bye-laws of the Company and the Listing Rules and the results of the poll will be published on the websites of the Stock Exchange and the Company in accordance with the Listing Rules.
2. All persons who are registered holders of the Shares on Monday, August 26, 2024, the record date for the Annual General Meeting, will be entitled to attend and vote at the meeting. In order to be entitled to attend and vote at the Annual General Meeting, all transfer documents, accompanied by the relevant share certificates, must be lodged with office of the Company's Hong Kong branch share registrar, Tricor Secretaries Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration no later than 4:30 p.m. on Monday, August 26, 2024.
3. Any Shareholder entitled to attend and vote at the above meeting is entitled to appoint a proxy to attend and vote instead of him/her. A proxy need not be a Shareholder. If more than one proxy is so appointed, the appointment shall specify the number and class of shares in respect of which each such proxy is so appointed. For the avoidance of doubt, holders of treasury Shares (if any) are not entitled to vote at the Annual General Meeting.
4. Any Shareholder whose ownership is either recorded through the Central Clearing and Settlement System (CCASS) or maintained with a licensed securities dealer (i.e., not directly recorded in his/her own name in the Register of Members of the Company) shall only be entitled to vote by providing its instructions to vote to HKSCC Nominees Limited either directly as a CCASS Participant or through its licensed securities dealer and the relevant financial intermediaries. In order to attend and vote at the meeting, any such Shareholder shall be appointed by HKSCC Nominees Limited as its proxy to attend and vote instead of him/her.
5. In order to be valid, the form of proxy must be deposited at the office of the Company's Hong Kong branch share registrar, Tricor Secretaries Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not less than 48 hours before the time appointed for the holding of the meeting or any adjournment thereof. Delivery of the form of proxy shall not preclude a Shareholder from attending and voting in person at the meeting and, in such event, the instrument appointing a proxy shall be deemed to be revoked.
6. As at the date of this notice, the Board comprises seven Directors, of whom (i) three are executive Directors, namely Mr. Zhu Shunyan, Mr. Shen Difan and Mr. Tu Yanwu; (ii) two are non-executive Directors, namely Ms. Huang Jiaojiao and Mr. Xu Haipeng; and (iii) three are independent non-executive Directors, namely Ms. Huang Yi Fei (Vanessa), Dr. Shao Rong and Ms. Wu May Yihong.
7. The Directors standing for re-election at the Annual General Meeting are Mr. Xu Haipeng, Ms. Huang Yi Fei (Vanessa), Dr. Shao Rong and Ms. Wu May Yihong.
8. In the event of a conflict between any translation and the English text hereof, the English text will prevail.